Elon Musk believes the device has the “potential to be better than natural vision”
Neuralink is developing a new implant – called Blindsight – with the aim of restoring vision to people suffering from total or partial blindness. Now, the Food and Drug Administration (FDA) appears to have considered this implant a “breakthrough device”.
The news was shared by Neuralink on its X social media page, with the designation applied by the FDA signaling the importance of accelerating the development and evaluation of the device. Elon Musk, one of the founders of Neuralink, took the opportunity to explain in more detail how Blindsight works.
“Neuralink’s Blindsight device will allow even those who have lost both eyes and the optic nerve to be able to see,” Musk wrote on X. “Assuming the cerebral cortex remains intact, it will even allow people who have been blind since birth to see for the first time.”
Musk noted, however, that initially the vision provided by Blindsight would have low resolution, but he believes that in the future there is “potential for it to be better than natural vision.”
No comments:
Post a Comment